Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on February 1, 2023, covering events occurring on that date. The Company is incorporated in Florida and its common stock trades on the NYSE American under the symbol "OGEN".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material event reported is the resolution of a listing deficiency. On February 1, 2023, the NYSE American notified the Company that it had regained compliance with the Exchange's continued listing standards. Specifically, the deficiency regarding the low selling price of the Company's common stock, as described in Section 1003(f)(v) of the NYSE American Company Guide, has been resolved.
Outlook, Risks, and Management Commentary
Going forward, the Company will be subject to the NYSE American's normal continued listing monitoring. The filing notes a specific risk: if the Company is determined to be noncompliant with any continued listing standards within the next twelve (12) months, the Exchange will examine the relationship between the previous noncompliance and the new event. Depending on the circumstances, the Exchange may implement truncated compliance procedures or immediately initiate delisting proceedings.
Key Facts for Investor Verification
- Oragenics has officially regained compliance with NYSE American listing standards regarding share price.
- The Company is now under normal monitoring rather than deficiency monitoring.
- A new noncompliance event within the next 12 months could trigger accelerated delisting procedures.
- No financial data or operational updates were included in this specific filing.